Neuvasq Biotechnologies appoints World-Leading Experts to newly formed Scientific Advisory Board dedicated to its CNS Barriers discovery platform
Neuvasq Biotechnologies (Neuvasq), a research and development company focused on advancing therapies that safeguard or rebuild CNS barriers and restore neurovascular function, announce the formation of its Scientific Advisory Board (SAB) comprising renowned experts in neurological diseases, genetics and neurovascular signaling pathways affecting CNS barriers:
Benoit Vanhollebeke, PhD (Chair of the SAB): Head of the Laboratory of Neurovascular Signaling at Université libre de Bruxelles (ULB), Belgium
Stefan Liebner, PhD: Head of the Blood-Brain Barrier Signaling Group, Edinger Institute, Goethe University Clinic Frankfurt, Germany
Britta Engelhardt, PhD: Director of the Theodor-Kocher-Institute, University of Bern, Switzerland
Matthew Campbell, PhD: Head of Department at the Smurfit Institute of Genetics, Trinity College Dublin, Ireland
Martin Dichgans, MD, PhD: Director, Institute for Stroke and Dementia Research (ISD), Ludwig-Maximilians-University Medical Center, Munich, Germany
The SAB members will support Neuvasq strategy, offering invaluable advice from their wide areas of expertise that spread across numerous neurovascular diseases, including stroke, dementia, epilepsy, multiple sclerosis, and vascular retinopathies and across different fields of research, including neurovascular signaling pathways and CNS barriers.
Benoit Vanhollebeke, Founder of Neuvasq Biotechnologies and SAB Chairman commented: “We are honored to welcome such esteemed experts in the field to our Scientific Advisory Board. Each brings her/his respective scientific expertise in key areas of interest to Neuvasq. Their deep understanding of the different mechanisms that govern CNS barriers will be instrumental in informing and guiding our development efforts toward therapies and diseases where our technology holds the greatest promise for improving patient outcomes.”
About Neuvasq Biotechnologies
Neuvasq Biotechnologies, a privately held research company, is dedicated to advancing pioneering therapies to safeguard or rebuild CNS barriers and improve neurovascular function for patients with severe neurological conditions. We engineered a first product, NVQ021, with the aim to offer an effective treatment for vascular retinopathies such as diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). In addition, we initiated discovery-stage programs to address BBB breakdown and neurovascular impairment in conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and/or epilepsy. The company is headquartered in Gosselies, Belgium. For more information, please visit www.neuvasq.com.
Cookie policy